



## Drug Manufacturers - Specialty & Generic / JP / 2022-08-23




### Owners Earnings, annually




*Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with B.axter Pharmaceuticals Ltd.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




TPCO Holding Corp., cultivates, extracts, manufactures, distributes, retails, and delivers cannabis in California. The company offers approximately 17 owned and licensed brands offering 250 stock keeping units across form-factors, such as jarred and bagged whole flower, pre-rolls, infused pre-rolls, bulk extracts, vaporizer cartridges, ready-to-use vapes, concentrates, gummies, chocolate, capsules, tinctures, topicals, and body care products. As of December 31, 2021, the Company operated eleven retail locations and six consumer delivery hubs; and four stores under the Caliva, Deli by Caliva, Coastal, and Calma brands, as well as through Caliva.com, a direct-to-consumer e-commerce platform. The company was formerly known as Subversive Capital Acquisition Corp. and changed its name to TPCO Holding Corp. in January 2021. TPCO Holding Corp. was incorporated in 2019 and is headquartered in San Jose, California.






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, and diagnostic products, instruments and reagents, and diagnostic products, instruments and reagents.






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23





## Owners Earnings, annually






Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, and diagnostic services from its subsidiaries.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, and laboratory services for animal health.





## Drug Manufacturers - Specialty & Generic / BD / 2022-08-23




## Owners Earnings, annually




*Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.*



## Drug Manufacturers - Specialty & Generic / IL / 2022-08-23





## Owners Earnings, annually




Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.






## Drug Manufacturers - Specialty & Generic / IL / 2022-08-23





## Owners Earnings, annually




Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.











## Drug Manufacturers - Specialty & Generic / IL / 2022-08-23






## Owners Earnings, annually





Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.










## Drug Manufacturers - Specialty & Generic / US / 2022-08-29



*Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers sterile ophthalmics solutions.*




## Drug Manufacturers - Specialty & Generic / US / 2022-08-29




*Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers sterile ophthalmics solutions.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually






PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23



*Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes. It also provides OEM, ODM, formulation design, research and development, and raw material supply services. The company was founded in 1969 and is headquartered in Taoyuan, Taiwan.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23





Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065015 for the treatment of pediatric patients.



## Drug Manufacturers - Specialty & Generic / IE / 2022-08-23




## Owners Earnings, annually




*Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including sterile solutions of various pharmaceuticals.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually






Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. The company also provides hemp-based CBD products. As of April 21, 2022, it operated 128 dispensaries and 26 cultivation sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




*Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.*






## Drug Manufacturers - Specialty & Generic / DE / 2022-08-23




## Owners Earnings, annually




Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health. It has collaboration agreements with Bayer AG; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Celgene; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.



## Drug Manufacturers - Specialty & Generic / IE / 2022-08-22






## Owners Earnings, annually




Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, including Europe, The Middle East, and Africa.








Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies in the Department of Defense, with the




### AMRX / Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies in the Department of Defense with the


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Owners Earnings, annually




*Green Thumb Industries Inc. engages in manufacture, distribution, and sale of various cannabis products for medical and adult-use in the United States. It offers cannabis flower; and processed and packaged products, including pre-rolls, concentrates, vapes, tinctures, edibles, topicals, and other cannabis-related products under the Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. The company distributes its products primarily to third-party retail stores, as well as sells finished products directly to consumers in its own retail stores. As of April 11, 2022, it owned and operated 77 retail stores in the United States. The company was founded in 2014 and is headquartered in Chicago, Illinois.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually








Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-22






Owners Earnings, annually





*Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.*






## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23




Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. It operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. The company provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. It offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. The company operates Tilray Medical, a medical platform that provides GMP-certified flowers, oils, vapes, edibles, and topicals. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Tilray, Inc. Tilray Brands Inc. was incorporated in 2018 and is headquartered in New York, New York.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The company produces flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands. As of March 16, 2022, it operated 162 dispensaries, which included 113 dispensaries in Florida, 19 affiliated dispensaries in Pennsylvania, 17 dispensaries in Arizona, five dispensaries in California, three dispensaries in Maryland, two dispensaries in Massachusetts, two dispensaries in West Virginia, and one dispensary in Connecticut. Trulieve Cannabis Corp. also operated cultivation and processing facilities in Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc. / Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. on September 20, 2019.




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / HK / 2022-08-23



Owners Earnings, annually




*Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually




*Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulinum Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera.*




## rug Manufacturers - Specialty & Generic / US / 2022-08-23




Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.





## Drug Manufacturers - Specialty & Generic / HK / 2022-08-23





## Owners Earnings, annually






*HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kδ (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma, and HMPL-286*





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23



Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23







Owners Earnings, annually




*Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of sialorrhea in patients with PD.*







Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly



Sales, NI &amp; Operating CF, annually



rug Manufacturers - Specialty &amp; Generic / GB / 2022-08-23




Owners Earnings, annually




Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually



*Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.*




## Drug Manufacturers - Specialty & Generic / HK / 2022-08-23




*HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kδ (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and solid tumors, and HMPL-286.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / FR / 2022-08-23




Owners Earnings, annually




*Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasitocides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually



Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23






## Owners Earnings, annually




Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.











## Drug Manufacturers - Specialty & Generic / IL / 2022-08-23






## Owners Earnings, annually





*Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes its products in the United States, Canada, Israel, and internationally.*



Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




*Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.*


Sales, NI &amp; Operating CF, quarterly



Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-29




Owners Earnings, annually




Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals,


Sales, NI &amp; Operating CF, quarterly



Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-29




Owners Earnings, annually




*Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals,*


Sales, NI &amp; Operating CF, quarterly



Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-29




Owners Earnings, annually




*Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals,*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23






Owners Earnings, annually





PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a variety of services, including pet training, pet sitting, and pet grooming.





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23



Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is **TYMLOS**, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

This waterfall chart illustrates the financial performance of a company from 2014 Q1 to 2021 Q1. The y-axis represents monetary values in millions, ranging from -40 M to 100 M. The x-axis shows time in quarters, with labels for 2014 Q1, 2015 Q1, 2016 Q1, 2017 Q1, 2018 Q1, 2019 Q1, 2020 Q1, and 2021 Q1. The chart is divided into three main components: revenue (dark blue), net income (light blue), and operating cash flow (pink). Revenue shows a steady increase over time, starting near 0 M in 2014 Q1 and reaching approximately 88 M by 2021 Q1. Net income and operating cash flow are shown as negative values (below the zero line) for the first part of the period, indicating losses. Net income starts at approximately -5 M in 2014 Q1 and reaches a low of about -25 M in 2017 Q1. Operating cash flow starts at approximately -5 M in 2014 Q1 and reaches a low of about -20 M in 2017 Q1. Both net income and operating cash flow show significant improvement starting in 2018 Q1, with net income reaching approximately 72 M and operating cash flow reaching approximately 38 M by 2021 Q1.

Quarter	Revenue (M)	Net Income (M)	Operating Cash Flow (M)
2014 Q1	0	-5	-5
2015 Q1	0	-5	-5
2016 Q1	0	-10	-10
2017 Q1	0	-25	-20
2018 Q1	35	-15	20
2019 Q1	40	-10	30
2020 Q1	45	-5	35
2021 Q1	88	72	38


The chart displays the daily number of COVID-19 cases in the Netherlands from June 2015 to June 2020. The y-axis represents the number of cases, ranging from 0.0 to 30.0. The x-axis shows time, with major ticks for 2015-06-30, 2017-12-31, and 2020-06-30. The data is represented by a solid blue area, and a dashed orange line indicates a trend or moving average. The chart shows a period of low case counts until early 2020, followed by a sharp increase to a peak of nearly 28 cases in May 2020, and then a period of fluctuation between 10 and 25 cases.

C


The chart displays the components of total stockholders' equity over time. The y-axis represents the amount in millions (M), ranging from 0 M to 800 M. The x-axis represents the years from 2000 to 2019. The components are stacked as follows: longTermDebt (dark blue), shortTermDebt (teal), cashAndCashEquivalents (pink), and totalStockholdersEquity (dark blue). The total stockholders' equity shows a significant increase starting around 2010, peaking in 2019.

Year	longTermDebt (M)	shortTermDebt (M)	cashAndCashEquivalents (M)	totalStockholdersEquity (M)
2000	0	0	0	0
2001	0	0	0	0
2002	0	0	0	0
2003	0	0	0	0
2004	0	0	0	0
2005	0	0	0	0
2006	0	0	0	0
2007	0	0	0	0
2008	0	0	0	0
2009	0	0	0	0
2010	0	0	0	0
2011	0	0	0	0
2012	0	0	0	0
2013	0	0	0	0
2014	0	0	0	0
2015	0	0	0	0
2016	0	0	0	0
2017	0	0	0	0
2018	0	0	0	0
2019	0	0	0	0


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.*

Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 31 dispensaries and 10 cultivation and/or processing facilities in 8 states. The company was founded in 2014 and is headquartered in New York, New York.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / GB / 2022-08-23




Owners Earnings, annually




Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23






## Owners Earnings, annually





Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, which then sell them to retail pharmacies.









## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23



Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is a public company listed on the Toronto Stock Exchange under the ticker symbol AUN.






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.*



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually




*Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly, a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / IE / 2022-08-23





Owners Earnings, annually



*Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.*






## g Manufacturers - Specialty & Generic / US / 2022-08-23




4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates in two segments, THC Cannabis and Cannabidiol (CBD) Wellness. It produces, cultivates, sells, and distributes cannabis and CBD. As of December 31, 2021, it operated six dispensaries in Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. In addition, the company sells equipment, supplies, and intellectual property to cannabis producers; imports and sale equipment and supplies; leases real estate properties to cannabis producers; offers consulting services; and operates cannabis dispensaries. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.







BDSI / 0 / 0 / 2022-08-23




Owners Earnings, annually




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually






*Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic agent for the treatment of heart failure.*





## ing Manufacturers - Specialty & Generic / US / 2022-08-23






Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23






*Bakhu Holdings, Corp. focuses on the production, manufacturing, and sale of cannabis-related byproducts for medical, food additive, and recreational use in the United States and the Caribbean. The company was formerly known as Planet Resources, Corp. and changed its name to Bakhu Holdings, Corp. in May 2009. Bakhu Holdings, Corp. was incorporated in 2008 and is based in Long Beach, California.*





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23






*OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.*





## ug Manufacturers - Specialty & Generic / CA / 2022-08-23








*Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.*



## ug Manufacturers - Specialty & Generic / CA / 2022-08-23




*Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.*




Red White & Bloom Brands Inc. engages in the cultivation and retail of cannabis products primarily in Michigan, Illinois, Massachusetts, Arizona, California, and Florida. The company is headquartered in Vancouver, Canada.




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



rug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually



*Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.*

The chart displays the following data series:


- revenue** (dark blue)
- netincome** (light blue)
- operatingCashFlow** (pink)

The Y-axis represents values in millions (M), ranging from -250 M to 100 M. The X-axis shows time periods from 2017 Q4 to 2021 Q3.


Period	revenue (M)	netincome (M)	operatingCashFlow (M)
2017 Q4	-1	-1	-1
2018 Q1	1	1	1
2018 Q2	2	2	2
2018 Q3	3	-200	3
2018 Q4	4	-10	4
2019 Q1	5	-20	5
2019 Q2	6	-30	6
2019 Q3	7	-40	7
2019 Q4	8	-170	8
2020 Q1	9	-30	9
2020 Q2	10	-40	10
2020 Q3	11	-50	11
2020 Q4	12	-60	12
2021 Q1	13	-70	13
2021 Q2	14	-80	14
2021 Q3	15	-90	15

0


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




*Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for*



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23



## Owners Earnings, annually




*MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



rug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually




*Goodness Growth Holdings, Inc. operates as a physician-led cannabis company in the United States. The company cultivates cannabis in environmentally friendly greenhouses; manufactures pharmaceutical-grade cannabis extracts; and sells its products through its network of Green Goods and other Goodness Growth branded retail dispensaries, as well as third-party dispensaries. As of March 11, 2022, it operated 18 dispensaries, which included 2 in Maryland, 8 in Minnesota, 4 in New Mexico, and 4 in New York; and offered wholesale cannabis products through third-party companies in Arizona, Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually





*ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.*





## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in San Francisco, California.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation, University of Kentucky, and Georgia Institute of Technology.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually





*MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.*




## Drug Manufacturers - Specialty & Generic / HK / 2022-08-23




*Stemtech Corporation, a stem cell nutrition company, develops and sells various dietary supplements. It offers stemrelease3, a stem cell enhancer, which supports the body's natural renewal system, a general sense of wellbeing, and telomeres health, as well as promotes youthful and healthy aging; StemFlo that supports optimal blood and healthy stem cell flow, protect the cardiovascular system from oxidative damage, boosts vitality, and promotes healthy aging; and MigraStem, a natural source of potent antioxidants, phytonutrients, fiber, and polysaccharides, which optimizes the migration of stem cells, enhance the immune system performance, support detoxification and anti-oxidative functions, enhances healthy longevity, and provide vitality and well-being. The company also provides OraStem that protects, strengthens, rejuvenates, restores, and supports teeth and gum function from the cellular level, as well as offer anti-oxidative and anti-microbial protection, supports tooth strength with essential minerals, helps to remove stains, brightens teeth in a natural and non-abrasive way, and freshens breath; and D5, a dietary supplement for (FME) SIV.*



## rug Manufacturers - Specialty & Generic / US / 2022-08-23



## Owners Earnings, annually



Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migraine; rHlgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

The chart illustrates the quarterly financial performance of the company from 2011 Q4 to 2021 Q4. The y-axis represents the amount in millions (M), ranging from -40 M to 30 M. The x-axis shows the quarters from 2011 Q4 to 2021 Q4. The legend indicates three metrics: revenue (dark blue), netIncome (light blue), and operatingCashFlow (pink).

Revenue is consistently positive, starting around 1 M in 2011 Q4 and growing to approximately 22 M by 2021 Q4. NetIncome is mostly negative, starting around -2 M in 2011 Q4 and reaching a low of about -29 M in 2020 Q4. OperatingCashFlow is mostly negative, starting around -1 M in 2011 Q4 and reaching a low of about -19 M in 2020 Q4. There is a significant positive spike in operatingCashFlow in 2021 Q4, reaching approximately 22 M.

Quarter	revenue	netIncome	operatingCashFlow
2011 Q4	1	-2	-1
2012 Q1	1	-2	-1
2012 Q2	1	-2	-1
2012 Q3	1	-2	-1
2012 Q4	1	-2	-1
2013 Q1	1	-2	-1
2013 Q2	1	-2	-1
2013 Q3	1	-2	-1
2013 Q4	1	-2	-1
2014 Q1	1	-2	-1
2014 Q2	1	-2	-1
2014 Q3	1	-2	-1
2014 Q4	1	-2	-1
2015 Q1	1	-2	-1
2015 Q2	1	-2	-1
2015 Q3	1	-2	-1
2015 Q4	1	-2	-1
2016 Q1	1	-2	-1
2016 Q2	1	-2	-1
2016 Q3	1	-2	-1
2016 Q4	1	-2	-1
2017 Q1	1	-2	-1
2017 Q2	1	-2	-1
2017 Q3	1	-2	-1
2017 Q4	1	-2	-1
2018 Q1	1	-2	-1
2018 Q2	1	-2	-1
2018 Q3	1	-2	-1
2018 Q4	1	-2	-1
2019 Q1	1	-2	-1
2019 Q2	1	-2	-1
2019 Q3	1	-2	-1
2019 Q4	1	-2	-1
2020 Q1	1	-2	-1
2020 Q2	1	-2	-1
2020 Q3	1	-2	-1
2020 Q4	1	-2	-1
2021 Q1	1	-2	-1
2021 Q2	1	-2	-1
2021 Q3	1	-2	-1
2021 Q4	1	-2	-1

The chart displays three financial metrics over a 12-year period. Revenue (blue bars) shows a steady increase from approximately 100M in 2010 to 380M in 2021. Net income (red bars) starts at about 10M in 2010, dips to -10M in 2011, and then fluctuates between 10M and 20M until 2019, before a sharp decline to -90M in 2021. Operating cash flow (green line) remains relatively stable around 50M from 2010 to 2019, then drops significantly to -100M in 2021. The right y-axis percentages are not explicitly labeled with values in the chart area.

Fiscal Year	Revenue (M)	Net Income (M)	Operating Cash Flow (M)
2010 FY	100	10	50
2011 FY	110	-10	50
2012 FY	120	10	50
2013 FY	130	10	50
2014 FY	140	20	50
2015 FY	150	10	50
2016 FY	160	10	50
2017 FY	170	10	50
2018 FY	180	20	50
2019 FY	190	10	50
2020 FY	350	-50	-50
2021 FY	380	-90	-100

The chart illustrates the financial structure of the company from 2010 to 2020. The components are stacked as follows: longTermDebt (dark blue), shortTermDebt (light blue), cashAndCashEquivalents (red), and totalStockholdersEquity (green). The Y-axis represents values in millions (M), ranging from 0 M to 225 M. The X-axis represents years from 2010 to 2020. The chart shows significant fluctuations, with a major peak in total equity around 2019, reaching over 200 M.


Year	Change in Net Income (M)
2010	-1.5
2011	-4.5
2012	-6.5
2013	-8.5
2014	-12.0
2015	-18.0
2016	-28.0
2017	-44.0
2018	-34.0
2019	-41.0
2020	-48.5
2021	-65.0

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of *Helicobacter pylori* infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Dabigatran) for the


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Unrivaed Brands, Inc. cultivates, produces, and retails medical and adult use cannabis products in California, Oregon, and Nevada. It also operates medical marijuana retail and adult use dispensaries, cultivation, and production facilities. The company was formerly known as Terra Tech Corp. and changed its name to Unrivaed Brands, Inc. in July 2021. Unrivaed Brands, Inc. was founded in 2010 and is based in Santa Ana, California.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / CA / 2022-08-23





Owners Earnings, annually



*Sundial Growers Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use markets; and private sale of recreational cannabis through corporate owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.*




## Drug Manufacturers - Specialty & Generic / CN / 2022-08-22




Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. The company is headquartered in Beijing, Beijing and currently employs 380 full-time employees. The firm provides health and well-being focused plant-based products by using its subsidiaries' and variable interest entities' vertically- and horizontally-integrated production, distribution and sales channels. The firm operates through three segments: developing, manufacturing and distributing of specialized fabrics, textile products and other by-products derived from an indigenous Chinese plant called Apocynum Venetum, known as Bluish Dogbane (Luobuma); planting, processing and distributing of traditional Chinese medicinal herbal products, as well as other pharmaceutical products (Herbal products), and planting, processing and distributing of green and organic agricultural produce, as well as growing and cultivating of Chinese Yew trees (Agricultural products). The company utilizes engineering technologies and biotechnologies to produce, among other products, Chinese herbal medicines,


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




Grove, Inc., through its subsidiaries, engages in developing, producing, marketing, and selling raw materials, white label products, and end consumer products containing the industrial hemp plant extract, cannabidiol. The company serves consumer markets, including the botanical, beauty care, pet care, and functional food sectors. It also operates annual tradeshow related to the CBD industry in the United States. The company was incorporated in 2018 and is headquartered in Henderson, Nevada.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually




Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-22




Owners Earnings, annually




*LFTD Partners Inc. focuses on acquiring companies that manufacture and sell branded hemp-derived products, e-liquid, disposable nicotine vapes, kratom, and kava products in the United States. The company, through its 50% interest in SmplyLifted LLC, sells tobacco-free nicotine pouches under the brand name FR3SH; and offers CBD-infused beverage and products. The company was formerly known as Acquired Sales Corp. and changed its name to LFTD Partners Inc. in September 2021. LFTD Partners Inc. was incorporated in 1986 and is based in Jacksonville, Florida.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / GB / 2022-08-23





Owners Earnings, annually



*ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, and lice in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is headquartered in New Malden, the United Kingdom.*




## ug Manufacturers - Specialty & Generic / US / 2022-08-23




*Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.*

Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / IL / 2022-08-23




Owners Earnings, annually




*IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.*








## ug Manufacturers - Specialty & Generic / US / 2022-08-23



### Owners Earnings, annually




Millennium Sustainable Ventures Corp. is a close-ended investment company. The firm primarily intends to effect a merger, capital stock exchange, asset acquisition, or other similar transaction with one or more businesses that have operations primarily in India. It seeks to invest in companies operating in the financial services sector, healthcare, infrastructure and consumer, retail, and hospitality sectors. The firm primarily invests in private equity of SMC Group. It was formerly known as Millennium India Acquisition Company Inc. Millennium Sustainable Ventures Corp. was formed on March 15, 2006 and is domiciled in the United States.




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




*C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. It offers packaged and wholesale flower, vaporizer pens, cured extracts, edibles, pre-rolls, tinctures, and topicals. The company was formerly known as Curlew Lake Resources Inc. and changed its name to C21 Investments Inc. in November 2017. C21 Investments Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of epinephrine for the treatment of conditions other than anaphylaxis; and AQST-306, a sublingual film formulation of epinephrine for the treatment of conditions other than anaphylaxis.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually



*AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2020.*

The chart displays the components of revenue, net income, and operating cash flow over time. The y-axis represents the amount in millions (M), ranging from 0 M to -3 M. The x-axis shows the time period from 2009 Q1 to 2021 Q1. The revenue section (top) shows a steady decline from 0 M to approximately -2.8 M. The net income section (middle) shows a steady decline from 0 M to approximately -2.8 M. The operating cash flow section (bottom) shows a steady decline from 0 M to approximately -2.8 M.

Quarter	Revenue (M)	Net Income (M)	Operating Cash Flow (M)
2009 Q1	0.0	0.0	0.0
2009 Q2	-0.1	-0.1	-0.1
2009 Q3	-0.2	-0.2	-0.2
2009 Q4	-0.3	-0.3	-0.3
2010 Q1	-0.4	-0.4	-0.4
2010 Q2	-0.5	-0.5	-0.5
2010 Q3	-0.6	-0.6	-0.6
2010 Q4	-0.7	-0.7	-0.7
2011 Q1	-0.8	-0.8	-0.8
2011 Q2	-0.9	-0.9	-0.9
2011 Q3	-1.0	-1.0	-1.0
2011 Q4	-1.1	-1.1	-1.1
2012 Q1	-1.2	-1.2	-1.2
2012 Q2	-1.3	-1.3	-1.3
2012 Q3	-1.4	-1.4	-1.4
2012 Q4	-1.5	-1.5	-1.5
2013 Q1	-1.6	-1.6	-1.6
2013 Q2	-1.7	-1.7	-1.7
2013 Q3	-1.8	-1.8	-1.8
2013 Q4	-1.9	-1.9	-1.9
2014 Q1	-2.0	-2.0	-2.0
2014 Q2	-2.1	-2.1	-2.1
2014 Q3	-2.2	-2.2	-2.2
2014 Q4	-2.3	-2.3	-2.3
2015 Q1	-2.4	-2.4	-2.4
2015 Q2	-2.5	-2.5	-2.5
2015 Q3	-2.6	-2.6	-2.6
2015 Q4	-2.7	-2.7	-2.7
2016 Q1	-2.8	-2.8	-2.8
2016 Q2	-2.9	-2.9	-2.9
2016 Q3	-3.0	-3.0	-3.0
2016 Q4	-3.1	-3.1	-3.1
2017 Q1	-3.2	-3.2	-3.2
2017 Q2	-3.3	-3.3	-3.3
2017 Q3	-3.4	-3.4	-3.4
2017 Q4	-3.5	-3.5	-3.5
2018 Q1	-3.6	-3.6	-3.6
2018 Q2	-3.7	-3.7	-3.7
2018 Q3	-3.8	-3.8	-3.8
2018 Q4	-3.9	-3.9	-3.9
2019 Q1	-4.0	-4.0	-4.0
2019 Q2	-4.1	-4.1	-4.1
2019 Q3	-4.2	-4.2	-4.2
2019 Q4	-4.3	-4.3	-4.3
2020 Q1	-4.4	-4.4	-4.4
2020 Q2	-4.5	-4.5	-4.5
2020 Q3	-4.6	-4.6	-4.6
2020 Q4	-4.7	-4.7	-4.7
2021 Q1	-4.8	-4.8	-4.8


The chart illustrates the components of the change in working capital over a 12-year period. Revenue (blue) shows a steady decline from approximately -400 M in 2009 to -800 M in 2020. Net income (orange) starts at -400 M in 2009, peaks at -550 M in 2013, and then fluctuates between -400 M and -500 M. Operating cash flow (green) is consistently positive, starting at 100 M in 2009 and peaking at 400 M in 2018. The total change in working capital (dark blue) shows a significant increase from -400 M in 2009 to -800 M in 2020.

Fiscal Year	Revenue (M)	Net Income (M)	Operating Cash Flow (M)	Total Change in Working Capital (M)
2009 FY	-400	-400	100	-400
2010 FY	-400	-400	100	-400
2011 FY	-450	-450	100	-450
2012 FY	-500	-500	100	-500
2013 FY	-550	-550	100	-550
2014 FY	-500	-500	100	-500
2015 FY	-550	-550	100	-550
2016 FY	-600	-600	100	-600
2017 FY	-650	-650	100	-650
2018 FY	-700	-700	400	-700
2019 FY	-800	-800	100	-800
2020 FY	-800	-800	100	-800


Year	Annual Change (thousands of employees)
2009	-10
2010	-90
2011	-40
2012	5
2013	-25
2014	-15
2015	-15
2016	-30
2017	5
2018	85
2019	5
2020	5

*Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. The company is based in Birkenhead, the United Kingdom.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually




*Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. on December 2, 2020. Kala Pharmaceuticals, Inc. is a public company listed on the New York Stock Exchange under the ticker symbol KALA.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Debt Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Nutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration with the National Health & Medical Research Council (NH&MRC) to develop a new omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration with the National Health & Medical Research Council (NH&MRC) to develop a new omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually





*Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Phentermine HCl tablets for bariatrics under the Adipex-P brand.*




## Manufacturers - Specialty & Generic / US / 2022-08-23




Generation Hemp Inc. engages in leasing industrial warehouse located in Denver, Colorado. The company was formerly known as Home Treasure Finders, Inc. and changed its name to Generation Hemp Inc. in August 2019. Generation Hemp Inc. was incorporated in 2008 and is based in Dallas, Texas.








## g Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide 1131, which is used for diagnostic industrial*






## Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




Endexx Corporation engages in the manufacturing and sale of cannabidiol (CBD)-based products for the health and wellness market. It provides CBD creams, oils, capsules, extracts, topicals, drinks, chocolates, and pet products, as well as hemp-derived health and beauty care products for supporting the therapeutic relief of pain and inflammation for humans and pets through its e-commerce site [cbdunlimited.com](https://cbdunlimited.com), as well as other online and in-store retailers. The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in May 2020. Endexx Corporation is headquartered in Cave Creek, Arizona.

Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-22








Owners Earnings, annually






Lowell Farms Inc. engages in the cultivation, extraction, manufacturing, sale, marketing, and distribution of cannabis products to retail dispensaries in California. The company provides flowers, vape pens, oils, extracts, chocolate edibles, mints, gummies, topicals, tinctures, and pre-rolls under the Lowell Herb Co., Lowell Smokes, Cypress Reserve, Flavor Extracts, Kaizen, House Weed, Moon, Altai, Humble Flower, Original Pot Company, and CannaStripe brands. It also offers manufacturing, extraction, and distribution services to third-party cannabis and cannabis branding companies. The company was formerly known as Indus Holdings, Inc. and changed its name to Lowell Farms Inc. in March 2021. Lowell Farms Inc. was founded in 2014 and is based in Salinas, California.
















## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23








## Owners Earnings, annually






*CordovaCann Corp., a cannabis-focused consumer products company, primarily provides services and investment capital to the processing, production, and retail vertical markets of the cannabis industry. As of February 14, 2022, it operated 14 stores under the Star Buds Cannabis Co. brand in Canada and the United States. The company was formerly known as LiveReel Media Corporation and changed its name to CordovaCann Corp. in January 2018. CordovaCann Corp. is based in Toronto, Canada.*





Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.




*High Sierra Technologies, Inc. focuses on the development of patents and other products used in the processing of recreational cannabis and industrial hemp. Its patent portfolio includes low odor cannabis and hemp for smoking or as the starting materials for producing low odor cannabis and hemp products or flavored cannabis and hemp products. The company is based in Reno, Nevada.*




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Gridiron BioNutrients, Inc. develops, markets, and sells cannabidiol products. The company offers capsules, oil, gummies, concentrates, water, beverages, hemp tinctures, and salves. It sells its products under the Gridiron BioNutrients and Gridiron MVP names through an online platform. The company was founded in 2014 and is based in Scottsdale, Arizona.








## g Manufacturers - Specialty & Generic / US / 2022-08-23



## Owners Earnings, annually




Indoor Harvest Corp. focuses on providing production platforms, mechanical systems, and complete custom designed build outs for controlled environment agriculture and building integrated agriculture for the cannabis industry. The company also provides consulting and other services. Indoor Harvest Corp. was founded in 2011 and is based in Austin, Texas.




Exactus, Inc. produces and supplies hemp-derived ingredients and feminized hemp genetics. It provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries. The company's specialty ingredients include CBD, CBG, CBN, and CBC isolates; CBD and CBG distillates; CBD water-soluble; CBD and CBG biomass; CBD AND CBG flowers; and CBD crude oil. It also provides a range of custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, supplements, and other products. The company is based in Delray Beach, Florida. Exactus, Inc. is a subsidiary of Ceed2Med, LLC.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



g Manufacturers - Specialty &amp; Generic / US / 2022-08-23






Owners Earnings, annually





*Stem Holdings, Inc. operates as a vertically-integrated cannabis products and technology company. It engages in the production, distribution, and sale of cannabis and cannabis-infused products. The company's brands include TJ's Gardens, TravisxJames, and Yerba Buena flower and extracts; Cannavore edible confections; Doseology, a CBD mass-market brand; and delivery-as-a-service brands of Budee and Ganjarunner e-commerce platforms. As of September 30, 2021, it had ownership interests in 29 state issued cannabis licenses, including 9 licenses for cannabis cultivation; 3 licenses for cannabis processing; 2 licenses for cannabis wholesale distribution; 3 licenses for hemp production; 7 cannabis dispensary licenses; and 5 licenses for adult-use medical retailers. The company was incorporated in 2016 and is headquartered in Boca Raton, Florida.*










## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Healthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based formulations in the United States and internationally. It offers heart health nutritional products; and neuro-products under the KETONOMICS name that enhance brain health, including memory, cognition, focus, and neuro-energy. The company also provides bergamot products in capsule form under the BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, and BergaMet SPORTSHEART products labels. It distributes bergamot products through its website and distribution sites. The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is based in Las Vegas, Nevada.




## ug Manufacturers - Specialty & Generic / US / 2022-08-23




Can B Corp. develops, manufactures, and sells cannabidiol (CBD) based products in the United States. The company provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, concentrates, and life style products through its Website and vending machines, and other medical professionals. It offers its products under the Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in February 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York.



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually







Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*MJ Holdings, Inc. operates in the medical marijuana business in Nevada. It offers cultivation and production management, consulting, and asset and infrastructure development services for the cannabis industry. The company is headquartered in Las Vegas, Nevada.*






## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23




## Owners Earnings, annually




*Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States. It offers flower products, such as indicas, sativas, and hybrids; and edibles, vape cartridges, pre-rolls, or concentrates. The company sells its products through dispensaries. Grown Rogue International Inc. is headquartered in Medford, Oregon.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





ug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually



*NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil, topical lotions and oils, massage oils, and internal pet products. The company also offers NutraHemp CBD products, including oral sprays, tinctures, pet drops, pain balms, and face creams; and nutraceutical oral spray products for sleep support and weight loss; and an appetite suppressant, as well as dietary and other products, such as sanitizer products. NutraLife BioSciences, Inc. sells its products through [nutrallifebiosciences.com](https://nutrallifebiosciences.com), as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.*




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




*Grapefruit USA, Inc. focuses on manufacturing and distribution of cannabis distillates, edibles, and cannabis products. It also offers cannabis advisory services for branding, compliance, packaging, extraction, edible manufacturing, and distribution logistics efforts. The company was formerly known as Grapefruit Boulevard Investments, Inc. and changed its name to Grapefruit USA, Inc. in January 2020. Grapefruit USA, Inc. was founded in 2017 and is based in Wilmington, Delaware.*







## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23



One World Products, Inc. produces and supplies various cannabis and hemp products worldwide. It provides cannabis, hemp, and hemp products, including derivatives in crude oil, distillate, and isolate forms. The company was formerly known as One World Pharma, Inc. and changed its name to One World Products, Inc. in November 2021. One World Products, Inc. is headquartered in Las Vegas, Nevada.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




BioQuest Corp. markets, packages, and distributes hemp-CBD based products in the United States. It intends to sell men's, women's, pet, and lifestyle products under the Vital-Q brand. The company was formerly known as Select-TV Solutions, Inc. and changed its name to BioQuest Corp. in November 2019. BioQuest Corp. was incorporated in 2011 and is based in Newport Beach, California. BioQuest Corp. was formerly a subsidiary of Algonquin Partners Inc.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually








Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually




*cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.*



The chart displays three financial metrics over time: revenue (dark blue), net income (light blue), and operating cash flow (pink). The y-axis represents values in millions, ranging from 0 to 1000 M. The x-axis shows quarters from 2002 Q4 to 2021 Q1. Revenue is the largest component, followed by operating cash flow, and net income is the smallest. All three metrics show a general upward trend over the period.

Quarter	revenue (M)	netIncome (M)	operatingCashFlow (M)
2002 Q4	100	10	10
2003 Q4	110	12	12
2004 Q4	120	14	14
2005 Q4	130	16	16
2006 Q1	140	18	18
2007 Q1	150	20	20
2008 Q1	160	22	22
2009 Q1	170	24	24
2010 Q1	180	26	26
2011 Q1	190	28	28
2012 Q1	200	30	30
2013 Q1	210	32	32
2013 Q3	220	34	34
2014 Q1	230	36	36
2015 Q1	240	38	38
2016 Q1	250	40	40
2017 Q1	260	42	42
2018 Q1	270	44	44
2019 Q1	280	46	46
2020 Q1	290	48	48
2021 Q1	300	50	50





Waterfall chart illustrating the components of financial performance (Revenue, Net Income, and Operating Cash Flow) over time, from 2008 Q3 to 2021 Q2. The Y-axis represents the amount in millions (M), ranging from -1 M to 0 M.

Legend:


- Revenue (Blue)
- Net Income (Orange)
- Operating Cash Flow (Green)

The chart shows that Revenue (Blue) is consistently positive, starting near 0 M and increasing to approximately 0.1 M by 2021 Q2. Net Income (Orange) shows a significant decline starting in 2009 Q4, reaching a low of approximately -1.1 M in 2010 Q4, followed by a recovery to near 0 M by 2011 Q4. Operating Cash Flow (Green) remains relatively stable, fluctuating between -0.1 M and 0.1 M throughout the period.



The chart illustrates the components of the change in equity over time. The left Y-axis represents the absolute change in equity in millions (M), ranging from -2 M to 300 M. The right Y-axis represents the percentage change in equity, ranging from -2 % to 16 %. The X-axis shows the fiscal years from 2008 to 2020.

Fiscal Year	Revenue (M)	Net Income (M)	Operating Cash Flow (M)	Total Change (M)	Percentage Change (%)
2008 FY	0	0	0	0	0 %
2009 FY	0	0	0	0	0 %
2010 FY	0	-1.8	-0.2	-2.0	-16 %
2011 FY	0	1.2	0.8	2.0	10 %
2012 FY	0	0	0	0	0 %
2013 FY	0	0	0	0	0 %
2014 FY	0	0	0	0	0 %
2015 FY	0	0	0	0	0 %
2016 FY	0	0	0	0	0 %
2017 FY	0	0	0	0	0 %
2018 FY	0	0	0	0	0 %
2019 FY	0	0	0	0	0 %
2020 FY	0	0	-0.28	-0.28	-2 %



4 M —

longTermDebt

shortTermDebt

cashAndCashEquivalents

totalStockholdersEquity

3 M —

3 M —

2 M —


2 M —

1 M —

1 M —


0 M —

0 M —






The bar chart displays the annual change in net assets from 2008 to 2020. The y-axis represents the change in net assets in millions of euros, ranging from -1.0 M to 0.0 M. The x-axis lists the years from 2008 to 2020. The bars show a significant decrease in 2010 and 2011, followed by a recovery and then a slight decline in 2019 and 2020.



Year	Change in Net Assets (M€)
2008	-0.05
2009	-0.05
2010	-1.25
2011	-0.85
2012	0.00
2013	0.00
2014	0.00
2015	0.00
2016	0.00
2017	0.00
2018	0.00
2019	-0.25
2020	-0.15



*Cannonau Corp. engages in developing cannabidiol based products. The company was formerly known as Pacific Blue Energy Corp. and changed its name to Cannonau Corp. in August 2019. Cannonau Corp. was incorporated in 2007 and is based in Skaneateles, New York.*




## g Manufacturers - Specialty & Generic / CH / 2022-08-23




*Cannabis Suisse Corp. engages in the cultivation, production, and distribution of over-the-counter products, recreational tobacco products, and medical CBD oils. The company sells its products through Swiss4Life, a retail brand for online selling, as well as a network of retailers. It provides health-related supplements, and face masks and disinfectants, as well as retails cigarettes. The company was formerly known as Geant Corp. and changed its name to Cannabis Suisse Corp. in February 2019. Cannabis Suisse Corp. was incorporated in 2016 and is based in Bell Gardens, California.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




*Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; and ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure, as well as Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




Kona Gold Beverage, Inc. develops and sells hemp and cannabidiol (CBD) products in the functional beverage and fitness markets in the United States. The company operates through two segments, Beverages and Distribution. It offers hemp energy drinks and CBD energy water; and alkaline waters, beverages for kids, energy drinks, fruit flavored sodas, low carb lemonade, healthy aloe juice drinks, and CBD-infused jellybeans. The company also sells merchandise and apparel, such as shirts, tanks, hats, and towels. It sells its products primarily to beverage distributors and resellers, retail grocery, smoke shops and specialty stores, wholesalers, merchandisers, vape shops, and convenience stores; and beverage services under the Kona Gold Hemp Energy Drinks, OOH LA LEMIN, and Highdrate names. The company was formerly known as Kona Gold Solutions, Inc. and changed its name to Kona Gold Beverage, Inc. in October 2020. Kona Gold Beverage, Inc. was incorporated in 1997 and is based in Melbourne, Florida.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually







Debt Manufacturers - Specialty &amp; Generic / US / 2022-08-22



Owners Earnings, annually




*Kaya Holdings, Inc., a vertically integrated legal marijuana enterprise, produces, distributes, and/or sells a range of cannabis products in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates two retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. The company also provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Debt Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually



*Cannabis Sativa, Inc., through its subsidiaries, primarily provides telemedicine online referral services for customers desiring medical marijuana cards in the United States. It operates through two segments, PrestoCorp and GKMP. The company offers PrestoDoctor, an online telemedicine platform, which provides access to physicians for getting a medical marijuana recommendation using video conferencing technology; and operates as a contract manufacturer of products containing hemp-based cannabidiol (CBD). Its products under development include Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC; Face Garden, an antioxidant moisturizing cream for the face; Body Garden, a moisturizing body lotion; Lip Garden, an emollient balm; and cut cream. The company also offers Wild Earth Naturals and hi branded men's and women's fashion tee shirts and sweatshirts, as well as caps and coffee mugs through Website, [wildearthnaturals.com](http://wildearthnaturals.com); owns a patented cannabis sativa plant strain known as Ecuadorian Sativa; and*




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




*Marijuana Company of America, Inc., together with its subsidiaries, develops, produces, and distributes cannabis and cannabidiol (CBD) products under the hempSMART brand name in the United States. The company offers hempSMART products comprising hempSMART Brain, a patented and formulated personal care consumer product for brain wellness; hempSMART Pain capsules for temporary relief of minor discomfort with physical activity; hempSMART Pain Cream to reduce minor discomfort and promote muscle relaxation; hempSMART Drops, a hemp CBD oil tincture drops; hempSMART Pet Drops for cats and dogs; hempSMART Face, a facial moisturizer; and hempSMART drink mix, an industrial hemp based powderized CBD drink through its web site and affiliate marketing programs. It also distributes hemp and CBD products, such as smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers through [www.cdistro.com](http://www.cdistro.com). The company was formerly known as Converge Global, Inc. and changed its name to Marijuana Company of America, Inc. in December 2015. Marijuana Company of America, Inc. was founded in 2005 and has a market capitalization of approximately \$1.2 billion as of August 23, 2022.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Guardian Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of*



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23








## Owners Earnings, annually




Thunder Energies Corporation engages in the production, distribution, and sale of a range of CBD and hemp-based consumer products in the United States. It offers CBD and hemp products, including hemp flower, pre-rolls, and hemp extracts in the form of tinctures and vaporizers, as well as hemp-derived supplements and cosmetics through e-commerce and wholesale distribution channel under The Hemp Plug brand. The company was incorporated in 2011 and is based in Hollywood, Florida.









PotNetwork Holdings, Inc., through its subsidiaries, engages in the development and sale of hemp-derived cannabidiol (CBD) oil products. It offers flavored and unflavored oils; vaping pens and additives; edibles, such as chewable gummies and lollipops; capsules; beverage energy/relaxation shots; topical application creams in various concentrations; dog and cat wellness products in various dosages and delivery formats; skin care, bath, and body products; and hemp flowers. The company provides its products under various brands, including Diamond CBD, Chill, Relax, MediPets, and Meds BioTech, as well as various other brands. It sells its products through distributors and resellers, as well as through its Website. The company is based in Fort Lauderdale, Florida.









## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23






## Owners Earnings, annually





Target Group Inc. cultivates, processes, and distributes curated cannabis products for the adult-use medical and recreational cannabis market in Canada. Its products include cannabis flower and extract pods for vaporizer use, cannabis pre-rolls, k-cup infused coffee and tea pods, infused cannabis beverages and edibles, infused topical products, and CBD wellness products. The company also offers Wisp, a single-use pre-measured pod and vaporizer system for consumers involved in vaporizing natural herbs, including cannabis. It has a collaboration agreement with cGreen, Inc for manufacturing and distributing the patent-pending THC antidote True Focus in the United States, Europe, and the Caribbean; and distribution, collaboration, and licensing agreement with Serious Seeds B.V. The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018. The company was incorporated in 2013 and is based in Hamilton, Canada.






## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23




*Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually






Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.





## Manufacturers - Specialty & Generic / US / 2022-08-23



Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States. The company offers advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name. It also provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name. In addition, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing homes, and ambulatory surgical centers.






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




*Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




Drug Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




*CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.*








## ug Manufacturers - Specialty & Generic / US / 2022-08-23





## Owners Earnings, annually




Golden Developing Solutions, Inc., together with its subsidiaries, engages in developing an online retail business for cannabidiol (CBD) products. It develops and operates an Internet website that offers CBD, hemp oil, and health/wellness related products, including vitamins, supplements, CBD based tinctures, vapes, soft-gels, and other products. The company was formerly known as Clean Hydrogen Producers, Ltd and changed its name to Golden Developing Solutions, Inc. in April 2017. Golden Developing Solutions, Inc. was incorporated in 1998 and is based in Fort Lauderdale, Florida.




Parallel Industries Inc. does not have significant operations. Previously, the company was involved in development and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. It focuses on development, licenses, production, and markets prescription and over-the-counter products. The company was formerly known as Easton Pharmaceuticals Inc. and changed its name to Parallel Industries Inc. in December 2020. Parallel Industries Inc. was founded in 1997 and is headquartered in Toronto, Canada.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Resonate Blends, Inc., a cannabis holding company, provides cannabis-based products. It also operates an online mobile marketing platform that provides various offers, discounts, alerts, and events schedules, such as happy hours, trivia night, and other campaigns. The company was formerly known as Textmunication Holdings, Inc. and changed its name to Resonate Blends, Inc. in December 2019. Resonate Blends, Inc. is based in Calabasas, California.*



## Manufacturers - Specialty & Generic / DE / 2022-08-23




## Owners Earnings, annually




*Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / CN / 2022-08-23






Owners Earnings, annually




*Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtong ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric*






## Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Black Bird Biotech Inc. provides various biotech products. It manufactures and distributes MiteXstream, a plant-based biopesticide for the eradication of spider mites. The company also manufactures and sells CBD Oils, gummies and pet treats, CBD-infused personal care products, and hand sanitizer gel and spray products under the Grizzly Creek Naturals brand name. In addition, it grows industrial hemp under the Montana Hemp pilot program. The company was formerly known as Digital Development Partners, Inc. and changed its name to Black Bird Biotech, Inc. in June 2021. Black Bird Biotech, Inc. is based in Flower Mound, Texas.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




g Manufacturers - Specialty &amp; Generic / CN / 2022-08-23




Owners Earnings, annually




*Shineco, Inc. engages in processing and distributing specialized fabrics, textiles, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum in the People's Republic of China. The company's specialized fabrics, textiles, and other byproducts are specialized textile and health supplement products to incorporate traditional Eastern medicines with various scientific methods. It also grows and cultivates yew trees, fast-growing bamboo willows, and scenic greening trees; and provides logistic services for agricultural products. The company is headquartered in Beijing, the People's Republic of China.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-22





### Owners Earnings, annually




*Veritas Farms, Inc. focuses on producing, marketing, and distributing hemp oils and extracts containing phytocannabinoids. The company's products include vegan capsules, gummies, tinctures, lotions, salves, vape oils, cream, and oral syringes. It markets and sells its products under the Veritas Farms brand name, as well as through white label and private label custom formulations for distributors and retailers. The company was formerly known as SanSal Wellness Holdings, Inc. and changed its name to Veritas Farms, Inc. in February 2019. Veritas Farms, Inc. is based in Fort Lauderdale, Florida.*




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




THC Therapeutics, Inc. operates in the wellness industry. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. The company was formerly known as Millennium Blockchain, Inc. and changed its name to THC Therapeutics, Inc. in September 2018. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada.




## Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




Pure Harvest Corporate Group, Inc. focuses on the acquisition and operation of licensed medical and recreational marijuana dispensaries, cultivation facilities, and production facilities. It also focuses on providing cannabis and hemp-derived health and wellness products; and applying education, research and development, and technology to various sectors. The company was formerly known as Pure Harvest Cannabis Group, Inc. and changed its name to Pure Harvest Corporate Group, Inc. in June 2020. Pure Harvest Corporate Group, Inc. was founded in 2004 and is based in Greenwood Village, Colorado.






## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23




## Owners Earnings, annually




FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.*

## Sales, NI & Operating CF, quarterly




### Price vs shares outstanding, quarterly



Sales, NI &amp; Operating CF, annually


ACUR / 0 / 0 / 2022-08-23




Owners Earnings, annually




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






ug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually




*Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, nutrition, supplement, cosmetic, and alternative medicine worldwide. The company focuses on delivering nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, and aging. Its products include hemp oils, vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods, and other products. The company markets its products in a range of formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. It also offers Cannabidiol oil to retailers in the vaping industry; and cannabinoid products. In addition, the company retails health, wellness, sports nutrition, and dietary supplement products. Earth Science Tech, Inc. offers its products through its retail store, clinics, pharmacies, as well as through online. The company was formerly known as Ultimate Novelty Corporation, which was later renamed to Earth Science Tech, Inc.*




## Drug Manufacturers - Specialty & Generic / US / 2022-08-22




The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer products, and pharmaceutical companies. The company has a license and research agreement with Shaare Zedek Scientific Ltd. to assess the synergistic impact of various combinations of the neuroprotective therapeutic in a preclinical model. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




Eco Innovation Group, Inc. focuses on the development of power booster for home and office applications that will reduce electric bills. It also provides other energy saving related technologies. Eco Innovation Group, Inc. is based in Van Nuys, California.



## ug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Mountain High Acquisitions Corp focuses on the acquisition and development of businesses and other assets within the hemp industry. The company is based in Scottsdale, Arizona.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually









Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23



Owners Earnings, annually




*GSRX Industries Inc., through its subsidiaries, engages in acquiring, developing, and operating retail cannabis dispensaries. It operates five cannabis dispensaries under the Green Spirit RX name in Puerto Rico; and a dispensary under The Green Room name in California. The company also owns and operates GetPureAndNatural.com, an e-commerce site that offers a range of hemp extract products. In addition, it focuses on the extraction, manufacture, distribution, and delivery of cannabis and cannabinoid products. The company was formerly known as Green Spirit Industries Inc. and changed its name to GSRX Industries Inc. in July 2018. GSRX Industries Inc. is headquartered in Dorado, Puerto Rico.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / CN / 2022-08-23




Owners Earnings, annually




China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, Xuejie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of July 31, 2021, its end-customer base includes 70 pharmaceutical companies, 12 chain pharmacies, and 59 hospitals in 10 provinces and municipalities in China, including Jiangsu, Hubei, Shandong, Guangdong, Liaoning, Anhui, Henan, Jiangxi, Heilongjiang, and Hainan. The company was founded in 2005 and is based in Taizhou, China.




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Debt Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers **BREXAFEMME** (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, *Ibrexafungerp*, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and *ibrexafungerp* that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for *ibrexafungerp*. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-22




Owners Earnings, annually






*Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.*





## Drug Manufacturers - Specialty & Generic / IL / 2022-08-23



PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.




## rug Manufacturers - Specialty & Generic / CA / 2022-08-22




*Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production and sale of medical cannabis for medical purpose in Canada. It offers dried cannabis strains, pre-rolls, ingestible extracts, and cannabis oil products to its medical patients. The company distributes its medical products through licensed wholesale pharmacies and to licensed wholesale clients. It also exports medical cannabis products to licensed wholesale purchasers in Europe. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually



PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.



## Manufacturers - Specialty & Generic / CN / 2022-08-23




China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. It offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, and hemp frozen age nourishing creams. The company also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, it offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, the company manufactures and sells various types


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-22



Owners Earnings, annually




*Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-22




Owners Earnings, annually




*Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic products that target the treatment of*



## Drug Manufacturers - Specialty & Generic / US / 2022-08-22




## Owners Earnings, annually




Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizer products. It also provides administrative, consulting, and operations support services to licensed cannabis companies. As of March 25, 2022, Ayr Wellness Inc. operated 45 dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




Drug Manufacturers - Specialty &amp; Generic / ES / 2022-08-22




Owners Earnings, annually




*Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for the central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein inhibitors; and a strategic collaboration with Boehringer Ingelheim to develop novel targeted protein inhibitors.*






## Drug Manufacturers - Specialty & Generic / US / 2022-08-22




## Owners Earnings, annually




Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23



## Owners Earnings, annually




*Viatrix Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually








Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23









Owners Earnings, annually







*Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.*












Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




Drug Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




*Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.*





## ug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Green Hygienics Holdings, Inc., a development stage company, focuses on the cultivation and processing of industrial hemp for the purpose of extracting cannabidiol. The company was formerly known as Takedown Entertainment Inc. and changed its name to Green Hygienics Holdings Inc. in July 2012. Green Hygienics Holdings, Inc. was incorporated in 2008 and is headquartered in Poway, California.*




ACCA / 0 / 0 / 2022-08-23




Owners Earnings, annually




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Big Manufacturers - Specialty &amp; Generic / US / 2022-08-23




Owners Earnings, annually




*ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.*



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually








rug Manufacturers - Specialty &amp; Generic / IL / 2022-08-23







Owners Earnings, annually




*Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection. It also provides KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thrombocytopenic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. For further information*











## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




Nunzia Pharmaceutical Corporation operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute NUNZIA, a drug that treats autism, fragile X, ADHD, and PTSD. It offers its products through wholesalers, as well as through its website [www.nunziapharma.com](http://www.nunziapharma.com). The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Corporation in February 2018. Nunzia Pharmaceutical Corporation was incorporated in 1986 and is based in Long Beach, California.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Owners Earnings, annually




*Harvest Health and Recreation, Inc., together with its subsidiaries, cultivates, processes, sells, and retails inhalable, ingestible, and topical cannabis products in the United States. The company offers cannabis oil products; inhalables, including flower, dabbable concentrates, pre-filled vaporizer pens, and cartridges; and capsules, tinctures, and cannabis product edibles, including chocolates, gummies, mints, fruit chews, and dissolvable mouth strips under the Avenue, CBX SCIENCES, EVOLAB, ALCHEMY, CHROMA, CO2LORS, GOODSUN, MODERN FLOWER, and ROLL ONE brand names. It also operates retail dispensaries that sell proprietary and third-party cannabis products to patients and customers; and provides support services and financing to a Utah licensed medical cannabis cultivator. Harvest Health and Recreation, Inc. was founded in 2011 and is headquartered in Tempe, Arizona.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually



*Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.*



## Manufacturers - Specialty & Generic / US / 2022-08-23




Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non-narcotic, non-addictive, and over-the-counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an anti-inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually



CURE Pharmaceutical Holding Corp., together with its subsidiaries, operates as a technology focused vertically integrated drug delivery and product development company in the pharmaceutical, and health and wellness markets. It focuses on the development and manufacturing of drug formulation and drug delivery technologies in novel dosage forms to enhance drug safety, efficacy, and patient adherence. The company operates through two business segments: Cure and Sera Labs. Its pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. The company also sells various wellness products under its distribution partners' brands. In addition, it is developing 50-200µg and 100-200µg D3 OTF for




## Drug Manufacturers - Specialty & Generic / IE / 2022-08-23




*Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Manufacturers - Specialty &amp; Generic / CA / 2022-08-23




Owners Earnings, annually




Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp-derived natural health products, including Liberty, a hemp-derived cannabidiol (CBD) tincture; Tactical Hydration, a CBD infused electrolyte replacement drink; FIZZ Tablets for adding in a water bottle; Battle Balm, a CBD roll on activity rub for aches and pains; and Quick Hit, a CBD gummy under the Tactical Relief brand. The company also provides Hydrosport CBD Drink, a CBD infused electrolyte replacement drink with sodium citrate electrolyte replacement; Hydrosport Tincture, a CBD tincture fortified with specific terpene profile; FIZZ Tablets for adding to a water bottle; Sport Rub, a CBD post-activity rub for aches and pains; and Quick Hit, a CBD gummy with vitamin B12 under the Equilibrium Bio brand. In addition, it offers Skin Structure, a facial formula topically applied to enhance skin's radiance and youthfulness; Eye Recover that helps the eye skin ward off free radicals, as well as helping to protect against sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer that









## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




New You, Inc., through its subsidiary, New You LLC, develops and markets cannabidiol (CBD) hemp oil-based products. The company offers DROPS beverage or liquid CBD products; CB2 & CBD 2 Plus, a multi spectrum hemp-extracted CBD and beta-caryophyllene; Drops for pets; Caffe Canna, an organic cannabinoid-infused non-GMO dark roast coffee; and ABSORB, a root and rice flour veggie capsule. It also provides RELEASE; Drops FX, a blend of CBD and Vitamins B3, B6, B9, and B12 for use in drink or liquid; and Drops FX Sleep, a blend of CBD, gamma-amino butyric acid, melatonin, and valerian root; NanoX, a water soluble full spectrum CBD made with Purified Water; and The Cream, a topical skin cream. The company markets and sells its products through multi-level marketing and direct sales force to independent business owners. New You, Inc. is based in Carlsbad, California.






## Manufacturers - Specialty & Generic / US / 2022-08-23





## Owners Earnings, annually




CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. It extracts cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. The company sells organic medical cannabis to licensed retailers; recreational marijuana cannabis products to licensed distributors and retailers; extraction products, such as oils and waxes derived from in-house cannabis production; processing and extraction services for licensed medical cannabis cultivators; and cannabis strains in the form of vegetative cuttings to licensed medical cannabis cultivators. It also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. The company provides its products under Oasis Cannabis and City Trees brand names. Its concentrates are used for pharmaceutical and other purposes. The company was founded in 2014 and is based in Miami, Florida.




## Drug Manufacturers - Specialty & Generic / IL / 2022-08-23




Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.




## Drug Manufacturers - Specialty & Generic / CA / 2022-08-23




## Owners Earnings, annually




HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. HEXO Corp. has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.



## Manufacturers - Specialty & Generic / US / 2022-08-23




## Owners Earnings, annually




*EVIO, Inc., together with its subsidiaries, provides analytical testing and advisory services to cannabis industry in the United States. The company's consulting services include advisory, product formulation, and licensing and compliance services. It also offers various testing services comprise cannabinoid potency testing, terpene analysis, pesticide testing, residual solvent screening, visual inspections, biological contaminant testing, and other services. EVIO, Inc. is headquartered in Henderson, Nevada.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





rug Manufacturers - Specialty &amp; Generic / US / 2022-08-23





Owners Earnings, annually






Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, pre-rolls, topicals, and other associated cannabis products; and vape cartridges and syringes. As of March 14, 2022, it owned and operated 23 retail cannabis dispensaries under the Star Buds, Smoking Gun Apothecary, Emerald Fields, and Drift banner names in Denver and Colorado; and 10 medical retail cannabis dispensaries under the R. Greenleaf banner in New Mexico. The company also provides licensing and consulting, facility design, and facility management services; and Three A Light publication. In addition, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is headquartered in Denver, Colorado.





## Drug Manufacturers - Specialty & Generic / DE / 2022-08-23



Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.




## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




*Pazoo, Inc. operates as a health and wellness company. It offers laboratory testing services for marijuana. Pazoo, Inc. was formerly known as IUCSS, Inc. and changed its name to Pazoo, Inc. in May 2011. The company was founded in 2010 and is headquartered in East Hanover, New Jersey.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually




## Drug Manufacturers - Specialty &amp; Generic / US / 2022-08-23






Owners Earnings, annually





SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and custom products worldwide. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Clindamycin Palmitate HCl, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexamethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrochloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydramine, 1-Benzhydrazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolidin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolidin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-2-(methylmino)-1-(2-thi-enyl)propan-1-ol, and (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol.






## Drug Manufacturers - Specialty & Generic / US / 2022-08-23




Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



Drug Manufacturers - Specialty &amp; Generic / NO / 2022-08-23




Owners Earnings, annually




*Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.*


Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually






Drug Manufacturers - Specialty &amp; Generic / GB / 2022-08-23





Owners Earnings, annually






*Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Alocclair, Anbesol, Asthon and Parsons, Atopicclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.*




## Drug Manufacturers - Specialty & Generic / CH / 2022-08-23




Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hypophosphatemia in CKD patients with kidney failure.



## Drug Manufacturers - Specialty & Generic / DE / 2022-08-23




## Owners Earnings, annually




MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually



rug Manufacturers - Specialty &amp; Generic / GB / 2022-08-23




Owners Earnings, annually




*Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in the wholesale and marketing of veterinary pharmaceuticals. The company serves customers in Spain, Portugal, Germany, Italy, other European countries, Asia, the Middle East, Africa, the United Kingdom, Belgium, the Netherlands, and internationally. Animalcare Group plc was incorporated in 1972 and is based in York, the United Kingdom.*




Sales, NI &amp; Operating CF, quarterly




Price vs shares outstanding, quarterly




Sales, NI &amp; Operating CF, annually





## Drug Manufacturers - Specialty &amp; Generic / CH / 2022-08-23




Owners Earnings, annually



*Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.*



## Drug Manufacturers - Specialty & Generic / GB / 2022-08-23



Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.